carmustine has been researched along with Lymph Node Metastasis in 24 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 9.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| " Inter-individual differences in the pharmacokinetic disposition of high-dose chemotherapy may explain variability in both response and toxicity." | 6.70 | Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. ( Berry, D; Broadwater, G; Colvin, OM; Gibbs, JP; Gilbert, CJ; Jones, RB; Peters, WP; Petros, WP; Vredenburgh, JJ, 2002) |
| "Seven hundred eighty-five women aged 22 to 66 years with stage IIA, IIB, or IIIA breast cancer involving 10 or more axillary lymph nodes were randomized after surgery and standard adjuvant chemotherapy to either high-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) with stem-cell support or intermediate-dose cyclophosphamide, cisplatin, and carmustine (ID-CPB) with G-CSF support but without stem cells." | 5.11 | Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA ( Cirrincione, C; Crump, M; Henderson, IC; Hurd, DD; Marks, LB; Norton, L; Peters, WP; Richardson, PG; Rosner, GL; Schilsky, RL; Schuster, MW; Shpall, EJ; Vredenburgh, JJ, 2005) |
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 5.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| "Thirty-three patients with malignant melanoma and regional lymph node metastases who underwent lymph node dissection were additionally given polychemotherapy with carmustine, hydroxycarbamide and dacarbazine immediately before surgery and up to five times postoperatively." | 5.06 | [Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma]. ( Aragon, V; Bröcker, EB; Bünte, H; Czarnetzki, BM; Krieg, V; Macher, E, 1986) |
| "Thirteen patients with advanced (Stage III) malignant melanoma have been treated with high-dose chemotherapy (nitrogen mustard or a combination of BCNU and melphalan) combined with autologous, nonfrozen, bone marrow transplantation." | 3.66 | Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study. ( Dantas, ME; Glode, LM; Koeppler, H; Morton, N; Robinson, WA; Sutherland, J; Thomas, MR, 1982) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| "Despite modern chemotherapy, advanced breast cancer remains a significant cause of cancer morbidity and mortality in women." | 2.70 | High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. ( Broadwater, G; Chao, NJ; Folz, RJ; Hussein, A; Long, GD; Marks, LB; Peters, WP; Rizzieri, D; Ross, M; Stuart, MJ; Vredenburgh, JJ, 2002) |
| " Inter-individual differences in the pharmacokinetic disposition of high-dose chemotherapy may explain variability in both response and toxicity." | 2.70 | Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. ( Berry, D; Broadwater, G; Colvin, OM; Gibbs, JP; Gilbert, CJ; Jones, RB; Peters, WP; Petros, WP; Vredenburgh, JJ, 2002) |
| "The prognosis for patients with primary breast cancer involving multiple axillary lymph nodes is poor." | 2.68 | Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II o ( Hurd, DD; Peters, WP, 1995) |
| "Forty-three patients are alive and breast cancer-free at a median of 947 days (range 661-1730 days) after the start of therapy, including one patient who developed myelodysplastic syndrome 809 days after the start of HDCT." | 2.68 | High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. ( Barón, AE; Bearman, SI; Bolwell, BJ; Cagnoni, PJ; Jones, RB; Mechling, BE; Overmoyer, BA; Purdy, MH; Ronk, B; Ross, M; Shpall, EJ; Taylor, CW, 1997) |
| "Patients with metastatic breast cancer (MBC) (median follow-up, 1." | 2.41 | High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. ( Blume, KG; Cecchi, GR; Damon, LE; Glaspy, J; Gold, E; Hu, WW; Irwin, D; Linker, CA; Mason, JR; Miller, W; Stockerl-Goldstein, KE; Territo, I; Wolf, JL, 2000) |
| "Esthesioneuroblastoma (olfactory neuroblastoma) is a rare neuroendocrine tumor that arises in the upper nasal cavity from the olfactory epithelium." | 2.40 | Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. ( Buckner, JC; Lewis, JE; McElroy, EA, 1998) |
| "The major limitation in the treatment of malignant melanoma is the lack of availability of effective agents for treatment." | 1.29 | Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. ( Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M, 1994) |
| "Nine instances of hepatic metastases were unaffected by therapy but 68% of the skin and nodal patients responded." | 1.26 | Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine. ( Cohen, SM; Greenspan, EM; Ratner, LH; Weiner, MJ, 1977) |
| "Skin, lymph node, and soft tissue metastases more frequently responded to therapy, while hepatic, peritoneal, and osseous metastases responded with an intermediate frequency." | 1.26 | Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma. ( Klahr, C; Presant, CA; Van Amburg, A, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (45.83) | 18.7374 |
| 1990's | 7 (29.17) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marks, LB | 3 |
| Cirrincione, C | 2 |
| Fitzgerald, TJ | 1 |
| Laurie, F | 1 |
| Glicksman, AS | 1 |
| Vredenburgh, J | 1 |
| Prosnitz, LR | 1 |
| Shpall, EJ | 4 |
| Crump, M | 2 |
| Richardson, PG | 2 |
| Schuster, MW | 2 |
| Ma, J | 1 |
| Peterson, BL | 1 |
| Norton, L | 2 |
| Seagren, S | 1 |
| Henderson, IC | 2 |
| Hurd, DD | 3 |
| Peters, WP | 6 |
| Stuart, MJ | 1 |
| Broadwater, G | 2 |
| Hussein, A | 1 |
| Ross, M | 3 |
| Folz, RJ | 1 |
| Long, GD | 1 |
| Rizzieri, D | 1 |
| Chao, NJ | 1 |
| Vredenburgh, JJ | 4 |
| Wolchok, JD | 1 |
| Williams, L | 1 |
| Pinto, JT | 1 |
| Fleisher, M | 1 |
| Krown, SE | 1 |
| Hwu, WJ | 1 |
| Livingston, PO | 1 |
| Chang, C | 1 |
| Chapman, PB | 1 |
| Rosner, GL | 1 |
| Schilsky, RL | 1 |
| Thomas, MR | 1 |
| Robinson, WA | 1 |
| Glode, LM | 1 |
| Dantas, ME | 1 |
| Koeppler, H | 1 |
| Morton, N | 1 |
| Sutherland, J | 1 |
| Schadendorf, D | 1 |
| Worm, M | 1 |
| Algermissen, B | 1 |
| Kohlmus, CM | 1 |
| Czarnetzki, BM | 2 |
| Meisenberg, BR | 1 |
| Jones, R | 1 |
| Seigler, HF | 1 |
| Coniglio, DM | 1 |
| Wu, K | 1 |
| Bearman, SI | 1 |
| Overmoyer, BA | 1 |
| Bolwell, BJ | 1 |
| Taylor, CW | 1 |
| Cagnoni, PJ | 1 |
| Mechling, BE | 1 |
| Ronk, B | 1 |
| Barón, AE | 1 |
| Purdy, MH | 1 |
| Jones, RB | 2 |
| McElroy, EA | 1 |
| Buckner, JC | 1 |
| Lewis, JE | 1 |
| Damon, LE | 1 |
| Hu, WW | 1 |
| Stockerl-Goldstein, KE | 1 |
| Blume, KG | 1 |
| Wolf, JL | 1 |
| Gold, E | 1 |
| Cecchi, GR | 1 |
| Irwin, D | 1 |
| Glaspy, J | 1 |
| Territo, I | 1 |
| Miller, W | 1 |
| Mason, JR | 1 |
| Linker, CA | 1 |
| Petros, WP | 1 |
| Berry, D | 1 |
| Gilbert, CJ | 1 |
| Gibbs, JP | 1 |
| Colvin, OM | 1 |
| Cohen, SM | 1 |
| Greenspan, EM | 1 |
| Ratner, LH | 1 |
| Weiner, MJ | 1 |
| Presant, CA | 1 |
| Van Amburg, A | 1 |
| Klahr, C | 1 |
| Costanzi, JJ | 1 |
| Vaitkevicius, VK | 1 |
| Quagliana, JM | 1 |
| Hoogstraten, B | 1 |
| Coltman, CA | 1 |
| Delaney, FC | 1 |
| Lopez, M | 1 |
| Natali, M | 1 |
| Di Lauro, L | 1 |
| Tonini, G | 1 |
| Carpano, S | 1 |
| Vici, P | 1 |
| Conti, EM | 1 |
| Basile, M | 1 |
| Moskowitz, B | 1 |
| Harris, J | 1 |
| Blumberg, N | 1 |
| Bennett, JM | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| McPherson, TA | 1 |
| Aragon, V | 1 |
| Bröcker, EB | 1 |
| Krieg, V | 1 |
| Bünte, H | 1 |
| Macher, E | 1 |
| Sulis, E | 1 |
| Floris, C | 1 |
| Chessa, A | 1 |
| Desogus, A | 1 |
| Muggiano, A | 1 |
| Tedde, A | 1 |
| Turno, R | 1 |
| Lewis, MB | 1 |
| Nunes, LB | 1 |
| Powell, DE | 1 |
| Shnider, BI | 1 |
| Garin, AM | 1 |
| Lichinitser, MR | 1 |
| Moroz, LV | 1 |
| Gutterman, JU | 1 |
| Mavligit, G | 1 |
| Gottlieb, JA | 1 |
| Burgess, MA | 1 |
| McBride, CE | 1 |
| Einhorn, L | 1 |
| Freireich, EJ | 1 |
| Hersh, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)[NCT05381038] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2022-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carmustine and Lymph Node Metastasis
| Article | Year |
|---|---|
Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1998 |
High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Calif | 2000 |
9 trials available for carmustine and Lymph Node Metastasis
| Article | Year |
|---|---|
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2010 |
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 2002 |
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antineoplastic Agents, Alkylating; Carmusti | 2003 |
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Chemother | 2005 |
Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II o
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmu | 1995 |
Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisp | 1993 |
High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car | 1997 |
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Weight; Breast Neoplas | 2002 |
[Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dacarbazine; | 1986 |
13 other studies available for carmustine and Lymph Node Metastasis
| Article | Year |
|---|---|
Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; | 1982 |
[Malignant melanoma].
Topics: Aminoimidazole Carboxamide; BCG Vaccine; Carmustine; Humans; Lymphatic Metastasis; Melanoma; Neck Di | 1981 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Rel | 1994 |
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasi | 1977 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Ascites; Bone Neoplasms; Breast Neoplasms; Carmustine; | 1977 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Epirubicin; | 1990 |
Malignant melanoma: primary presentation in bone marrow and lymph node.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cisplatin; Dacarbazine; | 1992 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com | 1987 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus | 1987 |
Extra-axial spread of medulloblastoma.
Topics: Autopsy; Brain Neoplasms; Carmustine; Cranial Fossa, Posterior; Femoral Neoplasms; Humans; Liver Neo | 1973 |
[Imidazole carboxamide in the treatment of disseminated melanoblastoma].
Topics: Amides; Carmustine; Humans; Hydroxyurea; Imidazoles; Lymphatic Metastasis; Melanoma; Neoplasm Metast | 1973 |
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Topics: Adult; Aged; Amides; Antibody Formation; Antineoplastic Agents; BCG Vaccine; Carmustine; Drug Therap | 1974 |